Charles River Laboratories International, Inc. Common Stock (CRL)

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks that produce reagents used in the ALA-101 manufacturing process.

Charles River Laboratories trades at $225.41 and has moved in lockstep with the market. Its shares have returned 11.4% over the last six months while the S&P...

Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors.

Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly).

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2nd, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 3rd, at 9:55 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.

Looking back on drug development inputs & services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Charles River Laborato...

Charles River Laboratories’ first quarter results reflected a mix of ongoing business transformation and operational adjustments. Management pointed to the i...

What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi...

Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River’s expertise in biologics and cell therapy GMP testing to support MEDIPOST’s global cell therapy pipeline, starting in the Asia-Pacific (APAC) and North America (NA) regions, with possible expansion into Middle East and Europe.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist efficiency, and supports the reduction of animal use in nonclinical research where scientifically appropriate.

Charles River Laboratories International (NYSE:CRL) reported first-quarter 2026 results that management said were in line to slightly ahead of its prior outlook, while reaffirming its full-year organic revenue and non-GAAP earnings guidance and outlining a refreshed strategic framework under new Chi

Charles River Laboratories (NYSE: CRL) beat Q1 earnings estimates but lowered its FY2026 forecast. Analysts maintain positive outlook with raised price targets.

Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 1.2% year on y...

Charles River (CRL) Q1 2026 Earnings Transcript

Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 1.2% year on ...

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2026. For the quarter, revenue was $995.8 million, an increase of 1.2% from $984.2 million in the first quarter of 2025.

Lab services company Charles River Laboratories (NYSE:CRL) will be reporting earnings this Thursday before market hours. Here’s what investors should know. C...

Charles River Laboratories today announced an enhanced In Vitro Fertility (IVF) service bundle designed to accelerate rat-model programs across therapeutics areas, including oncology, neurology, cardiology, and metabolic. By leveraging embryo transfer, cryopreservation, and colony rederivation, teams can rapidly recover lines, expand cohorts, and safeguard critical genotypes—while reducing downtime caused by breeding bottlenecks. This offering pairs dedicated project management with optional health monitoring and genetic validation to help ensure continuity across discovery, pharmacology, and translational studies. Researchers working in these therapeutic areas can request a streamlined quote and timeline starting this quarter to keep studies on track and data flowing.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such a...

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...